Dr. Christine Mummery appointed to Galapagos' Board of Directors
November 04 2015 - 1:36AM
Galapagos NV (Euronext & NASDAQ: GLPG) announced the
appointment of Dr. Christine Mummery to its Board of Directors as
an independent non-executive director.
Galapagos' Board of Directors has appointed Dr. Mummery to fill
the vacancy that has arisen on the Board as a result of the
resignation of Dr. Vicky Sato on 31 December 2014.
As of 2008, Dr. Christine Mummery is Professor of Developmental
Biology and Chair of the Department of Anatomy and Embryology at
the Leiden University Medical Centre (LUMC) in The
Netherlands. After her PhD in BioPhysics at London
University, she was postdoctoral fellow at the Hubrecht Institute
in Utrecht, later also staff member and group leader. She
became Professor at the Interuniversity Cardiology of the
Netherlands (ICIN) at the University Medical Centre Utrecht in
2002. In 2007, she was a joint Harvard Stem Cell
Institute/Radcliffe fellow at Harvard and Massachusetts General
Hospital at the time human induced pluripotent stem cells were
being developed and was the first to derive iPSC lines from
patients. Her primary research focus is currently the
development and use of stem cells in cardiovascular development and
disease.
She served on the Ethical Councils of the Ministry of Health, is
member of the Royal Netherlands Academy of Arts and Sciences
(KNAW), editor in chief/editorial board member of several journals,
former board member of ISSCR and past-president of the
International Society of Differentiation. In addition, she is
on the board of ZonMW (Dutch Medical Research Council) and chairs
the executive board of the hDMT Institute for human Organ and
Disease Model technologies, a non-profit R&D institute of which
Galapagos is a founding partner.
Dr. Mummery: "Galapagos is a great company, positioned to make a
difference in taking innovative drug discovery to patients. I
am honored to join the team in that process."
"We are very pleased that Christine has agreed to become a
member of the Galapagos Board of Directors. Her proven track
record of scientific research and accomplishments will make her an
excellent Board member," commented Onno van de Stolpe, CEO of
Galapagos.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action, with a
pipeline comprising three Phase 2 programs, two Phase 1 trials,
five pre-clinical studies, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other
indications. Filgotinib is an orally-available, selective
inhibitor of JAK1 for the treatment of rheumatoid arthritis and
potentially other inflammatory diseases. Galapagos has reported
good activity and a favorable safety profile in both the DARWIN 1
and 2 trials in RA. Galapagos is preparing to enter Phase 3
studies in RA and to report Phase 2 topline results with filgotinib
in Crohn's disease. In the field of cystic fibrosis, AbbVie
and Galapagos collaborate to develop and commercialize molecules
that address mutations in the CFTR gene. Potentiator GLPG1837
is expected to enter Phase 2 by end 2015, corrector GLPG2222 is
expected to enter Phase 1 by end 2015, and C2 corrector GLPG2665 is
expected to enter Phase 1 by mid 2016. GLPG1205, a first-in-class
inhibitor of GPR84 and fully-owned by Galapagos, will report
topline results in Q4 2015 from a Phase 2 proof-of-concept trial in
ulcerative colitis patients. GLPG1690, a fully proprietary,
first-in-class inhibitor of autotaxin, has shown favorable safety
in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More info
at www.glpg.com.
Contact
Investors: Media:
Elizabeth
Goodwin Evelyn
Fox VP IR & Corporate
Communications Director
Communications Tel: +1 781 460
1784 Tel: +31
6 53 591 999 E-mail:
ir@glpg.com E-mail:
communications@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, all of
which involve certain risks and uncertainties. These
statements are often, but are not always, made through the use of
words or phrases such as "believes," "anticipates," "expects,"
"intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," "continues," "we believe," "we intend," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which
might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Among the factors that may result
in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development
activities, regulatory approval requirements and estimating the
commercial potential of our product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in the company's Securities and Exchange Commission filing
and reports, including in the company's prospectus filed with the
SEC on May 14, 2015 and future filings and reports by the company.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
HUG#1963870
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024